Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma

Alexander M.M. Eggermont,Stefan Suciu,Alessandro Testori,Mario Santinami,Wim H. J. Kruit,Jeremy Marsden,Cornelis J.A. Punt,François Sales,Reinhard Dummer,Caroline Robert,Dirk Schadendorf,Poulam M. Patel,Gaetan de Schaetzen,Alan Spatz,Ulrich Keilholz

Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma

2012

Alexander M.M. Eggermont
Stefan Suciu
Alessandro Testori
Mario Santinami
Wim H. J. Kruit
Jeremy Marsden
Cornelis J.A. Punt
François Sales
Reinhard Dummer
Caroline Robert
Dirk Schadendorf
Poulam M. Patel
Gaetan de Schaetzen
Alan Spatz
Ulrich Keilholz

Purpose Adjuvant pegylated interferon alfa-2b (PEG-IFN--2b) was approved for treatment of resected stage III melanoma in 2011. Here, we present long-term follow-up results of this pivotal trial.

Keywords:

Melanoma
Stage III melanoma
Adjuvant therapy
Young adult
Pegylated interferon alfa-2b
Adjuvant
Oncology
Medicine
Pegylated interferon
Internal medicine
follow up studies
long term results

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

209

Citations